Innovassynth Q4 FY26: Order book strengthens as shipments normalize
Frequently Asked Questions
The presentation attributes the quarter’s impact to temporary shipment delays caused by logistics disruptions linked to the Middle East conflict and a one-time inventory adjustment by a key customer.
The company discloses an open order book of approximately INR 176 crore, comprising Life Sciences about INR 126 crore, Specialty Chemicals about INR 22 crore, and CRDMO about INR 28 crore.
The company states that a Life Sciences capacity expansion is underway and is expected to increase capacity by 2x, aligned with CDMO demand growth.
The presentation states it is an exports-led business with about 90% of revenue from global geographies, with key focus on the USA and Europe.
The company highlights ISO certifications and states it successfully completed audits from two large CDMO customers with no major observations, with two more audits scheduled in the coming months.
For FY26, the presentation reports revenue from operations of 10235, EBITDA of -2441, and PAT of -2878 (units as per the financial statement table in the presentation).
Did your stocks survive the war?
See what broke. See what stood.
Live Q1 Earnings Tracker